ÿþ<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"> <title>EASL 2010 - Poster Presentations</title> <link rel="stylesheet" type="text/css" href="style.css"> </head> <body> <table width="750" align="center" border="0" cellspacing="0" cellpadding="0" class="MainTable"> <tr> <td><img src="http://www2.kenes.com/liver-congress/PublishingImages/top_ei.jpg" width="760" height="129" /></td> </tr> <tr> <td class="content"><h1>Poster Presentations</h1> <P><b><u>Apr 17, 2010</u></b></P><p align=right><em>Poster Board Number</em></p><H2>Category 5f. VIRAL HEPATITIS: f. HEPATITIS C - CLINICAL (EXCEPT THERAPY):<br /></H2><table><tr> <td><a href='Abstract924.htm'><B>HCV INFECTION IMPAIRS GLUCOSE METABOLISM WHICH PROMOTES A MORE AGGRESSIVE COURSE OF LIVER DISEASE AND METABOLIC SYNDROME</B></a> </em><br> <b>L.E. Adinolfi</b><sup>1,2</sup>*, R. Zampino<sup>1</sup>, L. Restivo<sup>1,2</sup>, B. Guerrera<sup>1,2</sup>, A. Santoro<sup>2</sup>, A. Ciervo<sup>1,2</sup>, L. Rinaldi<sup>1,2</sup>, V.R. Scialdone<sup>1</sup>, M. Ferrara<sup>1</sup>, G. Ruggiero<sup>1</sup><br> <em><sup>1</sup>Internal Medicine & Hepatology, Second University of Naples, Naples, <sup>2</sup>Clinical Hospital of Marcianise, Second University of Naples, Marcianise, Italy. *luigielio.adinofi@unina2.it</em></td><td valign=top><em>1037 </td></tr> <tr> <td><a href='Abstract925.htm'><B>NATURAL HISTORY OF COMPENSATED CIRRHOSIS DUE TO CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC REVIEW</B></a> </em><br> <b>W. Alazawi</b><sup>1</sup>*, M. Cunningham<sup>1</sup>, J. Dearden<sup>2</sup>, G.R. Foster<sup>1</sup><br> <em><sup>1</sup>Centre for Digestive Diseases, Barts & The London School of Medicine, <sup>2</sup>Digestive Diseases Clinical Academic Unit, Barts & The London School of Medicine London NHS Trust, London, UK. *w.alazawi@qmul.ac.uk</em></td><td valign=top><em>1038 </td></tr> <tr> <td><a href='Abstract926.htm'><B>FIRST TIME EVALUATION OF CORONARY ARTERY CALCIUM SCORE (CACS) IN NON-CIRRHOTIC NAïVE HEPATITIS C VIRUS INFECTED PATIENTS: LEAN SUBJECTS ARE UNDER SIGNIFICANT CARDIOVASCULAR RISK </B></a> </em><br> S.S. Marini, P. Schvartzman, J. Bauer, C.A. Polanczyk, <b>M.R. Alvares-da-Silva</b>*<br> <em>Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. *mras@terra.com.br</em></td><td valign=top><em>1039 </td></tr> <tr> <td><a href='Abstract927.htm'><B>OCULAR FINDINGS IN NAïVE HEPATITIS C VIRUS INFECTED SUBJECTS: HIGH PREVALENCE OF OCULAR SURFACE ABNORMALITIES </B></a> </em><br> L.P. Zeni<sup>1</sup>, O.A. Birkhan<sup>1</sup>, M.T. Michalczuk<sup>1</sup>, M.A.P. Vilela<sup>2</sup>, <b>M. Alvares-da-Silva</b><sup>1</sup>*<br> <em><sup>1</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, <sup>2</sup>Universidade Federal de Pelotas, Pelotas, Brazil. *mras@terra.com.br</em></td><td valign=top><em>1040 </td></tr> <tr> <td><a href='Abstract928.htm'><B>HCV CORE PROTEIN INDUCES INTRAHEPATIC TGF-BETA ACTIVATION IN TRANSGENIC MICE</B></a> </em><br> <b>S. Battaglia</b><sup>1,2</sup>*, C. Guettier<sup>1,2,3</sup>, N. Benzoubir<sup>1,2</sup>, M. Gigou<sup>1,2</sup>, D. Samuel<sup>1,2,4</sup>, C. Brechot<sup>1,2,5</sup>, M.-F. Bourgeade<sup>1,2,4</sup><br> <em><sup>1</sup>Unite 785, INSERM, <sup>2</sup>UMR-S785, Univ Paris-Sud, Villejuif, <sup>3</sup>Service d'Anatomie Pathologique, AP-HP Hopital de Bicetre, Le Kremlin-Bicêtre, <sup>4</sup>Centre Hepato-Biliaire, AP-HP Hopital Paul Brousse, Villejuif, <sup>5</sup>Merieux Alliance, Lyon, France. *serena.battaglia@inserm.fr</em></td><td valign=top><em>1041 </td></tr> <tr> <td><a href='Abstract929.htm'><B>COMPARISON OF HEPATITIS C DONOR POSITIVE AND HEPATITIS C NEGATIVE GRAFTS IN HEPATITIS C POSITIVE KIDNEY TRANSPLANT RECIPIENTS</B></a> </em><br> <b>R. Battish</b><sup>1</sup>*, H. Shah<sup>1</sup>, J. Light<sup>2</sup>, A. Sherker<sup>3,4</sup><br> <em><sup>1</sup>Section of Gastroenterology and Hepatology, <sup>2</sup>Division of Transplant, <sup>3</sup>Center of Liver Diseases, Washington Hospital Center, <sup>4</sup>Georgetown University Medical Center, Washington, DC, USA. *raman.battish@gmail.com</em></td><td valign=top><em>1042 </td></tr> <tr> <td><a href='Abstract930.htm'><B>THERAPY RESPONSE</B> I<B>N CHRONIC HEPATITIS C PATIENTS IS AFFECTED BY COMMON <I>VITAMIN D RECEPTOR (NR 1I1) </I>POLYMORPHISMS</B></a> </em><br> <b>K. Baur</b><sup>1</sup>*, J. Mertens<sup>1</sup>, J. Schmitt<sup>1</sup>, R. Iwata<sup>1</sup>, B. Stieger<sup>2,3</sup>, P. Frei<sup>1</sup>, J. Braun<sup>4</sup>, B. Müllhaupt<sup>1,5</sup>, A. Geier<sup>1,3,5</sup><br> <em><sup>1</sup>Gastroenterology & Hepatology, <sup>2</sup>Clinical Pharmacology, University Hospital Zürich, <sup>3</sup>Zurich Center for Integrative Human Physiology (ZIHP), <sup>4</sup>Biostatistics Unit, Institute of Social und Preventive Medicine, University of Zürich, <sup>5</sup>Swiss Hepatopancreatobiliary (HPB)-Center, University Hospital Zürich, Zürich, Switzerland. *katharina.baur@usz.ch</em></td><td valign=top><em>1043 </td></tr> <tr> <td><a href='Abstract931.htm'><B>EVALUATION OF A NOVEL ULTRASOUND METHOD FOR THE DETECTION OF LIVER FIBROSIS- PROSPECTIVE COMPARISON WITH TRANSIENT DYNAMIC ELASTOGRAPHY AND HISTOLOGY </B></a> </em><br> <b>B. Boozari</b>*, A. Potthoff, I. Mederacke, A. Hahn, A. Reising, K. Rifai, H. Wedemeyer, S. Kubicka, M. Manns, M. Gebel<br> <em>Hannover Medical School, Hannover, Germany. *boozari.bita@mh-hannover.de</em></td><td valign=top><em>1044 </td></tr> <tr> <td><a href='Abstract932.htm'><B>SERUM OSTEOPROTEGERIN, A NEW SERUM MARKER OF LIVER FIBROSIS</B></a> </em><br> <b>N. Bosselut</b><sup>1,2,3</sup>*, J. Guéchot<sup>2</sup>, J.-P. Zarski<sup>4</sup>, V. Barbu<sup>1,3</sup>, E. Lasnier<sup>2</sup>, B. Baudin<sup>2</sup>, C. Housset<sup>1,3</sup>, M. Vaubourdolle<sup>2</sup>, ANRS HC EP 23 FIBROSTAR Study Group<br> <em><sup>1</sup>Inserm UMR_S938, CDR Saint-Antoine, <sup>2</sup>Biochemistry Laboratory, Saint-Antoine Hospital, AP-HP, <sup>3</sup>UPMC Univ Paris 06, Paris, <sup>4</sup>Hepatology Department, CHU Grenoble, Grenoble, France. *nelly.bosselut@htd.aphp.fr</em></td><td valign=top><em>1045 </td></tr> <tr> <td><a href='Abstract933.htm'><B>A NEW FIBROSIS STAGING METHOD PROVIDES VERY ACCURATE NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS WITHOUT LIVER BIOPSY</B></a> </em><br> <b>J. Boursier</b><sup>1</sup>*, V. de Ledinghen<sup>2</sup>, V. Leroy<sup>3</sup>, L. Castera<sup>2</sup>, J.P. Zarski<sup>3</sup>, F. Oberti<sup>1</sup>, S. Michalak<sup>1</sup>, Y. Gallois<sup>1</sup>, I. Fouchard-Hubert<sup>1</sup>, N. Dib<sup>1</sup>, M.C. Rousselet<sup>1</sup>, S. Bertrais<sup>1</sup>, P. Calès<sup>1</sup><br> <em><sup>1</sup>CHU, Angers, <sup>2</sup>Hôpital Haut-Lévêque, Pessac, <sup>3</sup>CHU, Grenoble, France. *jeboursier@chu-angers.fr</em></td><td valign=top><em>1046 </td></tr> <tr> <td><a href='Abstract934.htm'><B>COMPARISON OF LIVER FIBROSIS BLOOD TESTS DEVELOPED FOR HCV WITH NEW SPECIFIC TESTS IN HIV/HCV CO-INFECTION </B></a> </em><br> <b>P. Calès</b><sup>1</sup>*, P. Halfon<sup>2</sup>, D. Batisse<sup>3</sup>, F. Carrat<sup>4</sup>, P. Perré<sup>5</sup>, G. Penaranda<sup>2</sup>, D. Guyader<sup>6</sup>, L. D'alteroche<sup>7</sup>, I. Fouchard-Hubert<sup>1</sup>, C. Michelet<sup>8</sup>, P. Veillon<sup>1</sup>, J. Lambert<sup>4</sup>, L. Weiss<sup>9</sup>, D. Salmon<sup>10</sup>, P. Cacoub<sup>11</sup><br> <em><sup>1</sup>CHU, Angers, <sup>2</sup>Alphabio Laboratory, Marseille, <sup>3</sup>Hôpital Européen Georges Pompidou, <sup>4</sup>Hôpital Saint Antoine, Paris, <sup>5</sup>Centre Hospitalier, La Roche sur Yon, <sup>6</sup>Hôpital Pontchaillou, Rennes, <sup>7</sup>CHU, Tours, <sup>8</sup>CHU, Rennes, <sup>9</sup>Université Paris Descartes, <sup>10</sup>Hôpital Cochin, <sup>11</sup>Hôpital Pitié-Sapêtrière, Paris, France. *paul.cales@unvi-angers.fr</em></td><td valign=top><em>1047 </td></tr> <tr> <td><a href='Abstract935.htm'><B>ACCURACY OF LIVER FIBROSIS CLASSIFICATIONS</B> <B>PROVIDED BY NON-INVASIVE TESTS</B></a> </em><br> <b>P. Calès</b>*, J. Boursier, S. Bertrais, F. Oberti, Y. Gallois, I. Fouchard-Hubert, N. Dib, M.C. Rousselet, Multicentric Group<br> <em>CHU, Angers, France. *paul.cales@unvi-angers.fr</em></td><td valign=top><em>1048 </td></tr> <tr> <td><a href='Abstract936.htm'><B>ROBUSTNESS AND OPTIMIZATION OF AN ACCURATE BLOOD TEST FOR LIVER FIBROSIS </B></a> </em><br> <b>P. Calès</b>*, S. Bertrais, J. Boursier, F. Oberti, Y. Gallois, I. Hubert-Fouchard, N. Dib, M.C. Rousselet, Multicentric Group<br> <em>CHU, Angers, France. *paul.cales@unvi-angers.fr</em></td><td valign=top><em>1049 </td></tr> <tr> <td><a href='Abstract937.htm'><B>HEPATITIS C VIRUS INFECTION AND MORTALITY FROM LIVER RELATED DISEASE</B></a> </em><br> M.-H. Lee<sup>1,2</sup>, H.-I. Yang<sup>2</sup>, C.-L. Jen<sup>2</sup>, S.-L. You<sup>2</sup>, <b>C.-J. Chen</b><sup>1,2</sup>*, R.E.V.E.A.L-HCV Study Group<br> <em><sup>1</sup>National Taiwan University, <sup>2</sup>Genomics Research Center, Academia Sinica, Taipei, Taiwan R.O.C.. *cjchen@ntu.edu.tw</em></td><td valign=top><em>1050 </td></tr> <tr> <td><a href='Abstract938.htm'><B>HEPATITIS C VIRUS INFECTION ASSOCIATED WITH THE RISK OF CEREBROVASCULAR DISEASE</B></a> </em><br> M.-H. Lee<sup>1,2</sup>, H.-I. Yang<sup>2</sup>, C.-H. Wang<sup>3</sup>, C.-L. Jen<sup>2</sup>, S.-H. Yeh<sup>1</sup>, C.-J. Liu<sup>1</sup>, S.-L. You<sup>2</sup>, <b>C.-J. Chen</b><sup>1,2</sup>*<br> <em><sup>1</sup>National Taiwan University, <sup>2</sup>Genomics Research Center, Academia Sinica, <sup>3</sup>Cardinal Tien Hospital, Taipei, Taiwan R.O.C.. *cjchen@ntu.edu.tw</em></td><td valign=top><em>1051 </td></tr> <tr> <td><a href='Abstract939.htm'><B>THE FIBRO7-SCORE: A NOVEL SERUM PROTEOME- AND CLINICAL BIOCHEMISTRY-BASED PREDICTIVE MODEL FOR CHRONIC HEPATITIS C LIVER FIBROSIS</B></a> </em><br> <b>K.J. Cheung</b><sup>1</sup>*, K. Tilleman<sup>2</sup>, D. Deforce<sup>2</sup>, I. Colle<sup>1</sup>, H. Van Vlierberghe<sup>1</sup><br> <em><sup>1</sup>Dept. of Gastroenterology & Hepatology, Ghent University Hospital, <sup>2</sup>Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium. *kinjip.cheung@ugent.be</em></td><td valign=top><em>1052 </td></tr> <tr> <td><a href='Abstract940.htm'><B>ASSOCIATION BETWEEN DIABETES MELLITUS, HEPATIC STEATOSIS AND FIBROSIS IN CHRONIC HEPATITIS C PATIENTS IN TAIWAN</B></a> </em><br> <b>C.-Y. Dai</b><sup>1,2,3</sup>*, J.-F. Huang<sup>2,4</sup>, M.-Y. Hsieh<sup>2</sup>, N.-J. Hou<sup>4</sup>, Z.-Y. Lin<sup>2</sup>, S.-C. Chen<sup>2</sup>, L.-Y. Wang<sup>2</sup>, W.-L. Chuang<sup>2</sup>, M.-L. Yu<sup>2,5</sup><br> <em><sup>1</sup>College of Medicine, Kaohsiung Medical University, Kaohsiund, <sup>2</sup>Internal Medicine, <sup>3</sup>Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, <sup>4</sup>Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, <sup>5</sup>Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan R.O.C.. *daichaiyen@gmail.com</em></td><td valign=top><em>1053 </td></tr> <tr> <td><a href='Abstract941.htm'><B>MODERATE AND EXCESSIVE ALCOHOL INTAKE IMPACT TRANSPLANT-FREE SURVIVAL: A LONGITUDINAL STUDY IN HCV CIRRHOTIC PATIENTS</B></a> </em><br> <b>P. Deltenre</b><sup>1,2</sup>*, M. El Nady<sup>1</sup>, M. Corouge<sup>1</sup>, V. Canva<sup>1</sup>, A. Louvet<sup>1,3</sup>, H. Castel<sup>1,3</sup>, F. Wartel<sup>1</sup>, S. Dharancy<sup>1,3</sup>, J. Henrion<sup>2</sup>, P. Mathurin<sup>1,3</sup><br> <em><sup>1</sup>Service d'Hépato-Gastroentérologie, Hôpital Huriez, Lille, France, <sup>2</sup>Service d'Hépato-Gastroentérologie, Hopital de Jolimont, Haine-Saint-Paul, Belgium, <sup>3</sup>INSERM U795, Lille, France. *pierre.deltenre@skynet.be</em></td><td valign=top><em>1054 </td></tr> <tr> <td><a href='Abstract942.htm'><B>SEQUENCE EVOLUTION OF THE HCV NS3/4A PROTEASE DURING ACUTE HEPATITIS C VIRUS (HCV) INFECTION</B></a> </em><br> <b>J. Dietz</b><sup>1</sup>*, T. Lutz<sup>2</sup>, G. Knecht<sup>2</sup>, P. Gute<sup>2</sup>, A. Nehring<sup>1</sup>, B. Raziorrouh<sup>3</sup>, H. Diepolder<sup>3</sup>, S. Zeuzem<sup>1</sup>, C. Sarrazin<sup>1</sup><br> <em><sup>1</sup>Medizinische Klinik 1, Klinikum der J. W. Goethe-Universität, <sup>2</sup>Infektiologikum, Frankfurt/Main, <sup>3</sup>Medizinische Klinik II, Klinikum der Universität München-Grosshadern, München, Germany. *julia.dietz@em.uni-frankfurt.de</em></td><td valign=top><em>1055 </td></tr> <tr> <td><a href='Abstract943.htm'><B>DRIED BLOOD SPOT FOR HEPATITIS C VIRUS MOLECULAR DIAGNOSIS : AN ALTERNATIVE TOOL FOR HARD-TO-REACH POPULATION</B></a> </em><br> E. Tuaillon<sup>1,2</sup>, A.-M. Mondain<sup>1</sup>, F. Meroueh<sup>3</sup>, L. Ottomani<sup>1</sup>, P. Van de Perre<sup>1,2</sup>, <b>J. Ducos</b><sup>1,2</sup>*<br> <em><sup>1</sup>Laboratoire de Virologie, CHU Lapeyronie Montpellier, <sup>2</sup>EA 4205, Université Montpellier 1, <sup>3</sup>Pôle Urgences, CHU Lapeyronie Montpellier, Montpellier, France. *j-ducos@chu-montpellier.fr</em></td><td valign=top><em>1056 </td></tr> <tr> <td><a href='Abstract944.htm'><B>ENHANCED SURVEILLANCE OF REPORTED ACUTE HEPATITIS C IN CANADA, 1998 TO 2007</B></a> </em><br> <b>A.K. Dudani</b><sup>1,2</sup>*, H.-X. Wu<sup>1</sup>, Q. Li<sup>1</sup>, A. Andonov<sup>1</sup>, T. Wong<sup>1</sup>, G. Jayaraman<sup>1</sup>, K. Dinner<sup>1</sup>, J. Wu<sup>1</sup><br> <em><sup>1</sup>Public Health Agency of Canada, <sup>2</sup>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada. *anil_dudani@phac-aspc.gc.ca</em></td><td valign=top><em>1057 </td></tr> <tr> <td><a href='Abstract945.htm'><B>INSULIN RESISTANCE: A MAJOR PREDICTOR OF SIGNIFICANT LIVER FIBROSIS IN EGYPTIAN PATIENTS WITH GENOTYPE 4 CHRONIC HEPATITIS C</B></a> </em><br> <b>A. El Ray</b><sup>1</sup>*, R. Moucari<sup>2,3,4</sup>, M. El Ghannam<sup>1</sup>, A.A. Taha<sup>1</sup>, M.A. Saber<sup>5</sup>, M. Akl<sup>6</sup>, T. Asselah<sup>2,3,4</sup>, R. Atta<sup>1</sup>, M. Shemis<sup>5</sup>, A.S. Radwan<sup>7</sup>, A. Ghali<sup>1</sup>, V. Paradis<sup>8</sup>, P. Marcellin<sup>2,3,4</sup><br> <em><sup>1</sup>Hepatogastroenterology, Theodor Bilharz Research Institute, Giza, Egypt, <sup>2</sup>Hepatology, Beaujon Hospital, AP HP, Clichy, <sup>3</sup>INSERM, U773 CRB3, <sup>4</sup>Univ Paris 07, Paris, France, <sup>5</sup>Biochemistry-Molecular Biology, <sup>6</sup>Pathology, <sup>7</sup>Clinical Chemistry, Theodor Bilharz Research Institute, Giza, Egypt, <sup>8</sup>Pathology, Beaujon Hospital, AP HP, Clichy, France. *ahmedelray@hotmail.com</em></td><td valign=top><em>1058 </td></tr> <tr> <td><a href='Abstract946.htm'><B>POSSIBLE ROLE OF ANGIOTENSIN CONVERTING ENZYME POLYMORPHISM ON PROGRESSION OF HEPATIC FIBROSIS IN CHRONIC HEPATITIS C VIRUS INFECTION</B></a> </em><br> <b>Y. Elhosary</b>*, H.M. Raslan, N.A. Abdulla, K. Elsayed, W.M. Ezzat, H.E. El-Batae<br> <em>Hepatology, National Liver Institute, Cairo, Egypt. *yasserelhossary@yahoo.com</em></td><td valign=top><em>1059 </td></tr> <tr> <td><a href='Abstract947.htm'><B>ECONOMIC EVALUATION OF A MULTIDISCIPLINARY SUPPORT PROGRAM IN HEPATITIS C TREATMENT: PRELIMINARY RESULTS</B></a> </em><br> <b>M. García-Retortillo</b><sup>1</sup>*, V. Martín-Escudero<sup>2</sup>, M.D. Giménez<sup>1</sup>, I. Cirera<sup>1</sup>, C. Márquez<sup>1</sup>, P. Castellví<sup>1</sup>, O. Urbina<sup>3</sup>, E. Salas<sup>3</sup>, C. Varela<sup>2</sup>, R. Solà<sup>1</sup><br> <em><sup>1</sup>Liver Section, Hospital del Mar / IMIM / Universitat Autònoma de Barcelona, Barcelona, <sup>2</sup>Roche Pharma AG, Madrid, <sup>3</sup>Pharmacy Service, Hospital del Mar / IMIM, Barcelona, Spain. *97235@imas.imim.es</em></td><td valign=top><em>1060 </td></tr> <tr> <td><a href='Abstract948.htm'><B>MOLECULAR PATHWAYS LEADING TO INSULIN RESISTANCE IN HEPATITIS C VIRUS INFECTION</B></a> </em><br> <b>L.C. Godoy</b><sup>1</sup>*, R.G. Fonseca<sup>2</sup>, R.J. Carvalho-Filho<sup>1</sup>, C.T. Emori<sup>1</sup>, I.C. Melo<sup>1</sup>, V.P. Lanzoni<sup>3</sup>, C.P. Oliveira<sup>4</sup>, J.T. Stefano<sup>4</sup>, A.E.B. Silva<sup>1</sup>, J.B. Pesquero<sup>2</sup>, M.L.G. Ferraz<sup>1</sup><br> <em><sup>1</sup>Division of Gastroenterology, Hepatitis Section, Federal University of Sao Paulo, <sup>2</sup>Department of Biophysics, <sup>3</sup>Department of Pathology, Federal University of Sao Paulo, <sup>4</sup>Department of Gastroenterology, Faculty of Medicine of the University of Sao Paulo, Sao Paulo, Brazil. *lucascgodoy@uol.com.br</em></td><td valign=top><em>1061 </td></tr> <tr> <td><a href='Abstract949.htm'><B>NO EVIDENCE FOR AN IMPACT ON MORTALITY IN CHRONICALLY HCV INFECTED DRUG USERS</B></a> </em><br> <b>B.P.X. Grady</b><sup>1</sup>*, A. Krol<sup>1</sup>, C. van den Berg<sup>1</sup>, J. van der Helm<sup>1</sup>, J. Schinkel<sup>2</sup>, R. Coutinho<sup>1,3</sup>, M. Prins<sup>1</sup><br> <em><sup>1</sup>Infectious Diseases, Public Health Service Amsterdam, University of Amsterdam, <sup>2</sup>Department of Medical Microbiology, Academical Medical Center, Amsterdam, <sup>3</sup>Center for Infectious Disease Control, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. *b.grady@ggd.amsterdam.nl</em></td><td valign=top><em>1062 </td></tr> <tr> <td><a href='Abstract950.htm'><B>FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE DURING ACUTE HEPATITIS C VIRUS INFECTION</B></a> </em><br> <b>J. Grebely</b><sup>1</sup>*, G.J. Dore<sup>1</sup>, M. Schim van der Loeff<sup>2</sup>, A.L. Cox<sup>3</sup>, J. Bruneau<sup>4</sup>, A.Y. Kim<sup>5</sup>, A.R. Lloyd<sup>6</sup>, M. Hellard<sup>7</sup>, K. Page<sup>8</sup>, M. Prins<sup>2</sup>, on behalf of the InC3 Collaborative Group<br> <em><sup>1</sup>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands, <sup>3</sup>Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA, <sup>4</sup>CRCHUM, Université de Montréal, Montreal, QC, Canada, <sup>5</sup>Harvard Medical School, Boston, MA, USA, <sup>6</sup>School of Medical Sciences, University of New South Wales, Sydney, NSW, <sup>7</sup>Burnet Institute, Melbourne, VIC, Australia, <sup>8</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. *jgrebely@nchecr.unsw.edu.au</em></td><td valign=top><em>1063 </td></tr> <tr> <td><a href='Abstract951.htm'><B>ELISPOT TESTING SHOWS VERY FEW INJECTING DRUG USERS AVOID HEPATITIS C VIRUS EXPOSURE</B></a> </em><br> <b>M. Hellard</b><sup>1</sup>*, R. Sacks-Davis<sup>1</sup>, P. Higgs<sup>2</sup>, M. Bharadwaj<sup>3</sup>, D. Bowden<sup>4</sup>, H. Drummer<sup>5</sup>, C. Aitken<sup>1</sup><br> <em><sup>1</sup>Centre for Population Health, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, VIC, <sup>2</sup>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, <sup>3</sup>Department of Microbiology and Immunology, University of Melbourne, <sup>4</sup>Victorian Infectious Diseases Reference Laboratory, <sup>5</sup>Centre for Virology, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, VIC, Australia. *hellard@burnet.edu.au</em></td><td valign=top><em>1064 </td></tr> <tr> <td><a href='Abstract952.htm'><B>IMPACT OF SCREENING FOR HEPATOCELLULAR CARCINOMA (HCC) IN HIV/HCV-COINFECTED PATIENTS ON STAGING, THERAPY AND SURVIVAL</B></a> </em><br> <b>L. Kikuchi</b><sup>1</sup>*, M. Núñez<sup>2</sup>, P. Barreiro<sup>3</sup>, M. Nelson<sup>4</sup>, M.E. Vispo<sup>3</sup>, E. Page<sup>4</sup>, M. Puoti<sup>5</sup>, R. Fox<sup>6</sup>, M. Sherman<sup>7</sup>, F. Carrilho<sup>1</sup>, N. Bräu<sup>8,9</sup>, Liver Cancer in HIV Study Group<br> <em><sup>1</sup>Universidade de São Paulo, Sao Paulo, Brazil, <sup>2</sup>Wake Forest University, Winston-Salem, NC, USA, <sup>3</sup>Hospital Carlos III, Madrid, Spain, <sup>4</sup>Chelsea and Westminster Hospital, London, UK, <sup>5</sup>Università degli Studi di Brescia, Brescia, Italy, <sup>6</sup>University of California San Francisco, San Francisco, CA, USA, <sup>7</sup>University of Toronto, Toronto, ON, Canada, <sup>8</sup>Bronx Veterans Affairs Medical Center, Bronx, <sup>9</sup>Divisions of Infectious Diseases and Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA. *lu1912@gmail.com</em></td><td valign=top><em>1065 </td></tr> <tr> <td><a href='Abstract953.htm'><B>ACCELERATED FIBROSIS PROGRESSION IN HIV/HCV-COINFECTED PATIENTS UNDER EFFECTIVE ANTIRETROVIRAL THERAPY</B></a> </em><br> <b>J. Macías</b><sup>1</sup>*, M.A. von Wichmann<sup>2</sup>, A. Rivero<sup>3</sup>, F. Téllez<sup>4</sup>, D. Merino<sup>5</sup>, M. Márquez<sup>6</sup>, A. Vergara<sup>7</sup>, M. Delgado<sup>8</sup>, J.A. Mira<sup>1</sup>, J.A. Pineda<sup>1</sup>, Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (1, 3-8)<br> <em><sup>1</sup>Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, <sup>2</sup>Unidad de Enfermedades Infecciosas, Hospital de Donosti, San Sebastian, <sup>3</sup>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía, Cordoba, <sup>4</sup>Servicio de Medicina Interna, Hospital de la Línea, La Línea de la Concepción, <sup>5</sup>Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva, <sup>6</sup>Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de la Victoria, Malaga, <sup>7</sup>Unidad de Enfermedades Infecciosas, Hospital Universitario Puerto Real, Cadiz, <sup>8</sup>Unidad de Enfermedades Infecciosas, Hospital Universitario Carlos Haya, Malaga, Spain. *jmacias@cica.es</em></td><td valign=top><em>1066 </td></tr> <tr> <td><a href='Abstract954.htm'><B>EFFECT OF IRON DEPLETION ON INSULIN RESISTANCE IN PATIENTS WITH CHRONIC HEPATITIS C AND HYPERFERRITINEMIA</B></a> </em><br> <b>S. Montoliu</b>*, A. Pardo, M. Vargas, M. Papo, M. Menacho, B. Balleste, C. Abadia, J.C. Quer<br> <em>Gastroenterolgy, H. Universitari de Tarragona, Tarragona, Spain. *silvmontoliu@yahoo.es</em></td><td valign=top><em>1067 </td></tr> <tr> <td><a href='Abstract955.htm'><B>CIRCULATING FIBROCYTES AS A POTENTIAL NON INVASIVE MARKER OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION</B></a> </em><br> <b>G. Nunnari</b><sup>1</sup>*, C. Vancheri<sup>2</sup>, E. Gilli<sup>2</sup>, S. Migliore<sup>3</sup>, C. La Rosa<sup>2</sup>, R. Russo<sup>2</sup>, B. Cacopardo<sup>2</sup><br> <em><sup>1</sup>Medicine, <sup>2</sup>University of Catania, <sup>3</sup>University of Messina, Catania, Italy. *gnunnari@hotmail.com</em></td><td valign=top><em>1068 </td></tr> <tr> <td><a href='Abstract956.htm'><B>EVALUATION OF ANTIBODIES TO MULTIPLE CORE PEPTIDES IN PATIENTS WITH OCCULT HCV INFECTION</B></a> </em><br> <b>J.A. Quiroga</b><sup>1</sup>*, I. Castillo<sup>1</sup>, J. Bartolome<sup>1</sup>, S. Llorente<sup>1</sup>, G. Barril<sup>1,2</sup>, V. Carreño<sup>1</sup><br> <em><sup>1</sup>Fundacion para el Estudio de las Hepatitis Virales, <sup>2</sup>Nephrology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain. *fehvhpa@fehv.org</em></td><td valign=top><em>1069 </td></tr> <tr> <td><a href='Abstract957.htm'><B>EVIDENCE FOR CONSIDERABLE UNDERTREATMENT OF CHRONIC HEPATITIS C INFECTION IN HIV-HCV COINFECTED PATIENTS</B></a> </em><br> <b>T. Reiberger</b><sup>1</sup>*, M. Obermeier<sup>2</sup>, B.A. Payer<sup>1</sup>, A. Baumgarten<sup>3</sup>, A. Rieger<sup>4</sup>, M. Peck-Radosavljevic<sup>1</sup><br> <em><sup>1</sup>Internal Medicine III, Div. of Gastroenterology & Hepatology, Medical University Vienna, Vienna, Austria, <sup>2</sup>Medical Laboratory Berg, <sup>3</sup>Praxis Dupke/Carganico/Baumgarten, Berlin, Germany, <sup>4</sup>Dermatology, Div. of Immunology, Allergy & Infectious Diseases, Medical University Vienna, Vienna, Austria. *thomas.reiberger@meduniwien.ac.at</em></td><td valign=top><em>1070 </td></tr> <tr> <td><a href='Abstract958.htm'><B>SHORT AND LONG TERM OUTCOME OF KIDNEY TRANSPLANTED PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C</B></a> </em><br> <b>E. Ridruejo</b><sup>1</sup>*, G. Soler Pujol<sup>2</sup>, C. Díaz<sup>2</sup>, M. Dávalos Michel<sup>2</sup>, S. Marciano<sup>1</sup>, A. Martínez<sup>1</sup>, A. Vilches<sup>2</sup>, O.G. Mandó<sup>1</sup><br> <em><sup>1</sup>Viral Hepatitis Unit, Hepatology Section, Department of Medicine, <sup>2</sup>Nephrology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas  Norberto Quirno , CEMIC, Buenos Aires, Argentina. *eridruejo@gmail.com</em></td><td valign=top><em>1071 </td></tr> <tr> <td><a href='Abstract959.htm'><B>LOWER CUT-OFF LIMIT FOR ALANINE TRANSAMINASE IS NOT EFFECTIVE IN EXCLUDING SIGNIFICANT HISTOLOGICAL DISEASE IN CHRONIC HEPATITIS C (HCV)</B></a> </em><br> <b>F.M. Sanai</b><sup>1,2</sup>*, A.A. Abdo<sup>2,3</sup>, C.S. Dale<sup>4</sup>, A.S. Helmy<sup>5</sup>, K.I. Bzeizi<sup>1</sup>, K. Katada<sup>4</sup>, H. Al-Ashgar<sup>5</sup>, H. Al-Husseini<sup>1</sup>, M. Al-Quaiz<sup>5</sup>, A. Hashim<sup>6</sup>, H. AlMana<sup>5</sup>, M.H. Rajab<sup>7</sup>, P.J. Marotta<sup>4</sup><br> <em><sup>1</sup>Riyadh Military Hospital, <sup>2</sup>Liver Disease Research Center, <sup>3</sup>King Khalid University Hospital, Riyadh, Saudi Arabia, <sup>4</sup>London Health Sciences Center, London, ON, Canada, <sup>5</sup>King Faisal Specialist Hospital and Resaerch Center, Riyadh, <sup>6</sup>Saudi German Hospital, Jeddah, <sup>7</sup>Epidemiology, College of Medicine, AlFaisal University, Riyadh, Saudi Arabia. *faisalsanai@hotmail.com</em></td><td valign=top><em>1072 </td></tr> <tr> <td><a href='Abstract960.htm'><B>ITMN-191/R7227 MONOTHERAPY IN CHRONIC HCV PATIENTS REDUCES PLASMA CONCENTRATIONS OF IP-10 AND NEOPTERIN </B></a> </em><br> <b>C.J. Schaefer</b><sup>1</sup>*, K. Kossen<sup>1</sup>, S.R. Lim<sup>1</sup>, X. Qin<sup>1</sup>, J. Lin<sup>1</sup>, L. Pan<sup>1</sup>, W.Z. Bradford<sup>2</sup>, S.D. Seiwert<sup>1</sup><br> <em><sup>1</sup>Research, <sup>2</sup>Clinical Sciences, InterMune, Inc., Brisbane, CA, USA. *cschaefer@intermune.com</em></td><td valign=top><em>1073 </td></tr> <tr> <td><a href='Abstract961.htm'><B>INFLUENCE OF NICOTINE ABUSE ON FIBROSIS PROGRESSION IN CHRONIC HEPATITIS C VIRUS (HCV) INFECTION</B></a> </em><br> <b>A. Schäfer</b><sup>1</sup>*, S. Kriener<sup>2</sup>, K. Paul<sup>3</sup>, S. Zeuzem<sup>3</sup>, M. Scheurlen<sup>1</sup>, G. Teuber<sup>3,4</sup><br> <em><sup>1</sup>Med. Klinik und Poliklinik II, Universität Würzburg, Würzburg, <sup>2</sup>Senckenbergisches Institut für Pathologie, Klinikum der Goethe-Universität, <sup>3</sup>Medizinische Klinik I, Klinikum der Goethe-Universität, <sup>4</sup>IFS, Frankfurt/Main, Germany. *arne.schaefer@mail.uni-wuerzburg.de</em></td><td valign=top><em>1074 </td></tr> <tr> <td><a href='Abstract962.htm'><B>PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) ANALYSES OF TMC435 IN TREATMENT-NAIVE HEPATITIS C (HCV)-INFECTED PATIENTS IN THE OPERA-1 STUDY</B></a> </em><br> <b>V. Sekar</b><sup>1</sup>*, P. Vis<sup>2</sup>, O. Lenz<sup>2</sup>, P. Meyvisch<sup>2</sup>, M. Peeters<sup>2</sup>, G. De Smedt<sup>2</sup><br> <em><sup>1</sup>Tibotec Inc, Yardley, PA, USA, <sup>2</sup>Tibotec BVBA, Mechelen, Belgium. *vsekar@its.jnj.com</em></td><td valign=top><em>1075 </td></tr> <tr> <td><a href='Abstract963.htm'><B>EVALUATION OF METABOLIC INTERACTIONS FOR TMC435 VIA CYTOCHROME P450 (CYP) ENZYMES IN HEALTHY VOLUNTEERS</B></a> </em><br> <b>V. Sekar</b><sup>1</sup>*, R. Verloes<sup>2</sup>, P. Meyvisch<sup>2</sup>, K. Spittaels<sup>2</sup>, S.H. Akuma<sup>2</sup>, G. De Smedt<sup>2</sup><br> <em><sup>1</sup>Tibotec Inc, Yardley, PA, USA, <sup>2</sup>Tibotec BVBA, Mechelen, Belgium. *vsekar@its.jnj.com</em></td><td valign=top><em>1076 </td></tr> <tr> <td><a href='Abstract964.htm'><B>OXIDATIVE STRESS IS THE MAIN CAUSE OF STEATOSIS ESPECIALLY IN HCV GENOTYPE 3A. ASSOCIATION TO LIPID DEREGULATION IN THE ABSENCE OF INSULIN RESISTANCE</B></a> </em><br> C. Marinho<sup>1</sup>, <b>F. Serejo</b><sup>2</sup>*, C. Baldaia<sup>2</sup>, A. Esteves<sup>1</sup>, M. Bicho<sup>1</sup>, J. Velosa<sup>2</sup><br> <em><sup>1</sup>Genetics Laboratory/ Center of Metabolism and Endocrinology, Faculty of Medicine of Lisbon, <sup>2</sup>Gastroenterology, Hospital de Santa Maria, Lisbon, Portugal. *fatima_serejo@netcabo.pt</em></td><td valign=top><em>1077 </td></tr> <tr> <td><a href='Abstract965.htm'><B>HYPOCHOLESTEROLAEMIA IN CHRONIC HEPATITIS C GENOTYPE 3 INFECTION IS DUE TO BOTH REDUCED CHOLESTEROL PRODUCTION AND INCREASED LDL CLEARANCE</B></a> </em><br> <b>D. Sheridan</b><sup>1</sup>*, K. Bartlett<sup>2</sup>, D. Felmlee<sup>1</sup>, S.H. Bridge<sup>1</sup>, G.L. Toms<sup>1</sup>, G. Dubuc<sup>3</sup>, S. Nabil<sup>3</sup>, J. Davignon<sup>3</sup>, D. Neely<sup>1</sup>, M.F. Bassendine<sup>1</sup><br> <em><sup>1</sup>Institute of Cellular Medicine, Newcastle University, <sup>2</sup>Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, UK, <sup>3</sup>University of Montreal, Montreal, QC, Canada. *david.sheridan@ncl.ac.uk</em></td><td valign=top><em>1078 </td></tr> <tr> <td><a href='Abstract966.htm'><B>INSULIN RESISTANCE CORRELATES WITH LOW DENSITY HEPATITIS C VIRUS PARTICLES IN GENOTYPE 1 INFECTION</B></a> </em><br> S.H. Bridge<sup>1</sup>, <b>D.A. Sheridan</b><sup>1</sup>*, D.J. Felmlee<sup>1</sup>, S.U. Nielsen<sup>1</sup>, R.D.G. Neely<sup>2</sup>, G.L. Toms<sup>1</sup>, M.F. Bassendine<sup>1</sup><br> <em><sup>1</sup>Hepatology, Institute of Cellular Medicine, 4th Floor William Leech Building, Newcastle University, <sup>2</sup>Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, UK. *david.sheridan@newcastle.ac.uk</em></td><td valign=top><em>1079 </td></tr> <tr> <td><a href='Abstract967.htm'><B>DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF HEPATITIS C PATIENTS WITH AND WITHOUT DIABETES: THE MANAGED CARE EXPERIENCE</B></a> </em><br> <b>N.J. Shire</b><sup>1</sup>*, V.A. Shvachtko<sup>2</sup>, R.C. Murphy<sup>2</sup>, J.A. Darbanian<sup>2</sup>, J.M. Arduino<sup>3</sup>, M.M. Manos<sup>2</sup><br> <em><sup>1</sup>Experimental Medicine, Merck, North Wales, PA, <sup>2</sup>Division of Research, Kaiser Permanente Northern California, Oakland, CA, <sup>3</sup>Epidemiology, Merck, North Wales, PA, USA. *norah_shire@merck.com</em></td><td valign=top><em>1080 </td></tr> <tr> <td><a href='Abstract968.htm'><B>MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) - 493 G/T POLYMORPHISM IS ASSOCIATED WITH </B><B>FIBROSIS IN CHRONIC HEPATITIS C</B><B> (CHC) GENOTYPE 1 INFECTED PATIENTS</B></a> </em><br> <b>E.R. Siqueira</b><sup>1</sup>*, C.M. Oliveira<sup>2</sup>, T.J. Stefano<sup>2</sup>, A.M. Cavaleiro<sup>2</sup>, M. Fortes<sup>2</sup>, M.T. Muniz<sup>3</sup>, K.A. Silva<sup>3</sup>, F.S. Silva<sup>3</sup>, M.L. Correa-Gianella<sup>2</sup>, L.M. Pereira<sup>4</sup>, F.J. Carrilho<sup>2</sup>, São Paulo University and Liver Institute of Pernambuco<br> <em><sup>1</sup>Gastroenterology, São Paulo University, Recife, <sup>2</sup>São Paulo University, São Paulo, <sup>3</sup>Pernambuco University, <sup>4</sup>Liver Institute of Pernambuco, Recife, Brazil. *erfs@usp.br</em></td><td valign=top><em>1081 </td></tr> <tr> <td><a href='Abstract969.htm'><B>A PROSPECTIVE EVALUATION BY PAIRED BIOPSY OF FIBROSIS PROGESSION IN HIV-HCV COINFECTION COMPARED TO HCV MONOINFECTION</B></a> </em><br> <b>R. Sterling</b><sup>1</sup>*, J.A. Wegelin<sup>2</sup>, P.G. Smith<sup>1</sup>, V.A. Luketic<sup>1</sup>, R.T. Stravitz<sup>1</sup>, M. Fuchs<sup>1</sup>, P. Puri<sup>1</sup>, M.L. Shiffman<sup>1</sup>, A.J. Sanyal<sup>1</sup><br> <em><sup>1</sup>Gastroenterology, Hepatology, and Nutrition, <sup>2</sup>Biostatistics, Virginia Commonwealth University, Richmond, VA, USA. *rksterli@vcu.edu</em></td><td valign=top><em>1082 </td></tr> <tr> <td><a href='Abstract970.htm'><B>FACTORS ASSOCIATED WITH FIBROSIS IN CHRONIC HEPATITIS C FEMALE PATIENTS: IMPACT OF MENOPAUSE</B></a> </em><br> <b>C. Stern</b>*, A.-C. Cardoso, R.J. Carvalho-Filho, N. Boyer, R. Moucari, P. Bedossa, P. Marcellin<br> <em>Service d'Hépatologie, Hôpital Beaujon, Clichy, France. *christiane.stern@gmail.com</em></td><td valign=top><em>1083 </td></tr> <tr> <td><a href='Abstract971.htm'><B>INDEPENDENT VALIDATION OF THE SAFE BIOPSY ALGORITHM: ANALYSIS OF THE ACHIEVE COHORTS</B></a> </em><br> <b>A. Thompson</b><sup>1</sup>*, P. Clark<sup>2</sup>, H. Tillmann<sup>2</sup>, M. Torbenson<sup>3</sup>, E. Pulkstenis<sup>4</sup>, G.M. Subramanian<sup>4</sup>, J. McHutchison<sup>1</sup>, K. Patel<sup>2</sup><br> <em><sup>1</sup>Duke Clinical Research Institute, Duke University Medical Centre, <sup>2</sup>GI / Hepatology Research Program, Duke Clinical Research Insitiute, Duke University, Durham, NC, <sup>3</sup>Pathology Department, Johns Hopkins University School of Medicine, Baltimore, <sup>4</sup>Human Genome Sciences, Inc., Rockville, MD, USA. *alexander.thompson@duke.edu</em></td><td valign=top><em>1084 </td></tr> <tr> <td><a href='Abstract972.htm'><B>VIRAL HEPATITIS B AND C IN NEWLY DIAGNOSED HIV-1 INDIVIDUALS IN SPAIN - A NATIONAL SURVEY SINCE YEAR 2000</B></a> </em><br> <b>A. Treviño</b><sup>1</sup>*, C. Rodriguez<sup>2</sup>, P. Parra<sup>1</sup>, P. Rivas<sup>1</sup>, M.D. Herrero-Mendoza<sup>1</sup>, J. del Romero<sup>2</sup>, V. Soriano<sup>1</sup>, C. de Mendoza<sup>3</sup><br> <em><sup>1</sup>Hospital Carlos III, <sup>2</sup>Centro Sanitario Sandoval, <sup>3</sup>Infectious Diseases, Hospital Carlos III, Madrid, Spain. *ana.trevino.rc@gmail.com</em></td><td valign=top><em>1085 </td></tr> <tr> <td><a href='Abstract973.htm'><B>THE ASSOCIATION OF CRYOGLOBULINEMIA AND SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C</B></a> </em><br> <b>A. Vigani</b>*, A. Macedo-de-Oliveira, R. Tozzo, M.H. Pavan, E.S. Gonçales, V. Fais, N.S. Gonçales, F.L. Gonçales, Grupo de Estudos das Hepatites Virais - Unicamp<br> <em>Clinica Médica, Universidade Estadual de Campinas - Unicamp, Campinas, Brazil. *viganialine@hotmail.com</em></td><td valign=top><em>1086 </td></tr> <tr> <td><a href='Abstract974.htm'><B>PROTEIN PATHWAY BIOMARKERS PREDICTING SUSTAINED VIROLOGIC RESPONSE (SVR)TO PEGYLATED INTERFERON (PEG-IFN) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C (CH-C)</B></a> </em><br> <b>Z. Younossi</b><sup>1,2</sup>*, D. Limongi<sup>3</sup>, M. Stepanova<sup>1,2</sup>, M. Pierobon<sup>3</sup>, A. Afendy<sup>1,2</sup>, L. Liotta<sup>3</sup>, E. Petricoin<sup>3</sup><br> <em><sup>1</sup>Betty and Guy Beatty Center for Integrated Research, Inova Health System, <sup>2</sup>Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, <sup>3</sup>Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA. *zobair.younossi@inova.org</em></td><td valign=top><em>1087 </td></tr> <tr> <td><a href='Abstract975.htm'><B>IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) ON LIFE EXPECTANCY AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN CHRONIC HEPATITIS C (CHC) PATIENTS</B></a> </em><br> S. Cure<sup>1</sup>, F. Bianic<sup>1</sup>, H. Cawston<sup>1</sup>, L. Cawston<sup>1</sup>, <b>F. Zhang</b><sup>2</sup>*<br> <em><sup>1</sup>i3 Innovus, Uxbridge, UK, <sup>2</sup>WWHE&P, Raritan, NJ, USA. *hzhang20@its.jnj.com</em></td><td valign=top><em>1088 </td></tr> <tr> <td><a href='Abstract976.htm'><B>ASSOCIATION OF COMMON <I>P53</I> AND <I>MDM2 </I>VARIANTS WITH SPONTANEOUS AND TREATMENT INDUCED VIRAL CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION</B></a> </em><br> <b>V. Zimmer</b><sup>1</sup>*, F. Grünhage<sup>1</sup>, M. Krawczyk<sup>1</sup>, G. Assmann<sup>2</sup>, S. Zeuzem<sup>3</sup>, C. Sarrazin<sup>3</sup>, F. Lammert<sup>1</sup><br> <em><sup>1</sup>Department of Medicine II, <sup>2</sup>Department of Medicine I, Saarland University Hospital, Homburg, <sup>3</sup>Department of Medicine I, JW Goethe University Hospital, Frankfurt/Main, Germany. *invzim@uks.eu</em></td><td valign=top><em>1089 </td></tr> </table><a href='index.asp'>Back</a><br> <p>&nbsp;</p> <p>&nbsp;</p></td> </tr> </table> </body> </html>